Clinical Trial: Therapeutic Strategy in Advanced Bronchioloalveolar Carcinoma

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Effect of an Early Therapeutic Permutation on the Tumoral Control of Patients Receiving in First Line a Specific Inhibitor of Tyrosin Kinase of EGFR (Erlotinib) or a Taxan-based Chemotherapy for the T

Brief Summary: To evaluate among patients with untreated advanced ADC-CBA, impact on the disease control rate after 4 months treatment of an early therapeutic permutation with the first month in the absence of stabilization or objective answer.

Detailed Summary:
Sponsor: Intergroupe Francophone de Cancerologie Thoracique

Current Primary Outcome: 16-week Disease Control Rate [ Time Frame: 4-week ]

Original Primary Outcome: 4-month Disease Control Rate

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Intergroupe Francophone de Cancerologie Thoracique

Dates:
Date Received: October 5, 2006
Date Started: September 2006
Date Completion:
Last Updated: February 12, 2015
Last Verified: February 2015